,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-04-16 06:47:00,"Sunpeaks Ventures, Inc. (SNPK) completed its initial financing in March 2012 and hasn't looked back since.",0.0624447725713253,0.009927722625434399,0.9276275038719177,neutral,0.05251704901456833
1,2012-04-16 06:47:00,"Sunpeaks, and its wholly owned subsidiary Healthcare Distribution Specialties LLC (""HDS""), is focusing on value-added distribution of specialty drugs and over-the-counter (OTC) branded multivitamins to the healthcare provider market across the U.S.

Sunpeaks is a new player in the over $300 billion U.S. pharmaceutical market.",0.8116092085838318,0.01188688538968563,0.17650394141674042,positive,0.7997223138809204
2,2012-04-16 06:47:00,The company is currently focusing on gaining market share in the secondary wholesale market - and estimated $45 billion opportunity.,0.9076597690582275,0.012119390070438385,0.08022081106901169,positive,0.8955403566360474
3,2012-04-16 06:47:00,"Quite simply, Sunpeaks does not need to capture big market share to generate significant revenues in the coming years.",0.3560482859611511,0.0099243875592947,0.6340273022651672,neutral,0.34612390398979187
4,2012-04-16 06:47:00,"HDS is a wholesale distributor of a wide range of over 6,000 specialty drugs.",0.07286837697029114,0.004211613908410072,0.9229199886322021,neutral,0.06865676492452621
5,2012-04-16 06:47:00,HDS currently provides three primary distribution services and owns one over-the-counter (OTC) product.,0.018277475610375404,0.006302220746874809,0.975420355796814,neutral,0.011975254863500595
6,2012-04-16 06:47:00,"In additional to the company's distribution business, HDS owns and markets Clotamin, the world's first specialized over-the-counter multivitamin product designed exclusively for use by patients on warfarin and other blood thinners.",0.2196570783853531,0.006047756411135197,0.7742952108383179,neutral,0.21360932290554047
7,2012-04-16 06:47:00,"Blood thinners, including warfarin, when combined with Vitamin K, can cause dangerous shifts in a patient's international normalized ratio ( INR ) level - the time it takes a sample of blood to clot.",0.028615856543183327,0.9185885190963745,0.052795618772506714,negative,-0.8899726867675781
8,2012-04-16 06:47:00,"If your ratio is too high, it means it takes longer for your blood to clot and you may have an increased risk for uncontrollable bleeding.",0.03642094507813454,0.8684425354003906,0.09513653814792633,negative,-0.8320215940475464
9,2012-04-16 06:47:00,"If your INR falls below the normal levels, your blood may clot too quickly and increase your risk for a stroke.",0.026326870545744896,0.9328509569168091,0.040822118520736694,negative,-0.9065240621566772
10,2012-04-16 06:47:00,Physician's prescribing blood thinning agents may recommend patients also take a daily multivitamin.,0.03448152169585228,0.030247388407588005,0.9352710843086243,neutral,0.004234133288264275
11,2012-04-16 06:47:00,"However, off-the-shelf multivitamins contain Vitamin K, a blot clotting agent.",0.02416056953370571,0.020797424018383026,0.9550420641899109,neutral,0.0033631455153226852
12,2012-04-16 06:47:00,"Clotamin is a unique formulation of 12 essential vitamins customized for patient on blood thinning agents, without Vitamin K. Over 30 million prescriptions are written each year in the U.S. for warfarin.",0.08325190097093582,0.007523423992097378,0.9092246890068054,neutral,0.07572847604751587
13,2012-04-16 06:47:00,We see a sizable opportunity with Clotamin.,0.7225787043571472,0.010543987154960632,0.26687726378440857,positive,0.7120347023010254
14,2012-04-16 06:47:00,A two month supply retails for $25.99.,0.0734751746058464,0.01745852455496788,0.909066379070282,neutral,0.056016650050878525
15,2012-04-16 06:47:00,That's a peak opportunity of $4.7 billion for HDS.,0.6222383975982666,0.011151965707540512,0.366609662771225,positive,0.6110864281654358
16,2012-04-16 06:47:00,"Over the past few months, HDS has been working to expand the distribution channel for Clotamin.",0.9357218742370605,0.013524938374757767,0.050753261893987656,positive,0.9221969246864319
17,2012-04-16 06:47:00,"The company has locking in agreements with Walgreens ( WAG ), Navarro Discount Pharmacies, Bravo Supermarkets, and Winn-Dixie.",0.868423581123352,0.019170714542269707,0.11240573227405548,positive,0.8492528796195984
18,2012-04-16 06:47:00,The company is conducting a national advertising campaign to spread awareness and education on Clotamin.,0.43783918023109436,0.010589531622827053,0.5515713095664978,neutral,0.42724964022636414
19,2012-04-16 06:47:00,"We expect this to include television commercials, infomercials, direct-response commercials, and Internet-related media marketing.",0.023261534050107002,0.004893491510301828,0.9718449711799622,neutral,0.01836804300546646
20,2012-04-16 06:47:00,"Former NBA basketball coach and nominee for the Naismith Basketball Hall of Fame, Paul Silas, is the national spokesperson for Clotamin.",0.11104053258895874,0.009618686512112617,0.8793408274650574,neutral,0.10142184793949127
21,2012-04-16 06:47:00,"In early April 2012, HDS entered into a strategic sales and marketing agreement with Acosta Sales & Marketing, one of the leading sales and marketing agencies in the consumer packaged goods industry.",0.9150503873825073,0.012504416517913342,0.07244517654180527,positive,0.9025459885597229
22,2012-04-16 06:47:00,Acosta has a long established track record of helping to grow products into major national brands.,0.8438218235969543,0.011959768831729889,0.14421840012073517,positive,0.8318620324134827
23,2012-04-16 06:47:00,"The company has over $50 billion in system wide annual sales and close to 20,000 associates that call on over 100,000 retail stores per month.",0.07391626387834549,0.0056665632873773575,0.9204172492027283,neutral,0.06824970245361328
24,2012-04-16 06:47:00,"Acosta represents more #1 and #2 brands in North America than any other agency, and has major retail customers including Procter & Gamble ( PG ) and Walmart ( WMT ).",0.3028239905834198,0.008458919823169708,0.6887171268463135,neutral,0.2943650782108307
25,2012-04-16 06:47:00,Former NBA head coach Paul Silas isn't the only sport-marketing avenue is seeking to leverage.,0.028113078325986862,0.012810141779482365,0.9590767621994019,neutral,0.015302936546504498
26,2012-04-16 06:47:00,"On April 5, 2012, the company signed a Pass-Through Sponsorship Letter Agreement with Portland Trail Blazers.",0.8939281105995178,0.01429571583867073,0.09177611768245697,positive,0.8796324133872986
27,2012-04-16 06:47:00,"HDS gets the right to use the Trail Blazers name and logo on in-store promotions in all the Walgreens stores in the entire State of Oregon and the Southern Washington area, and will receive advertising space in the Rose Garden Arena for home basketball games.",0.43874597549438477,0.010289371013641357,0.5509646534919739,neutral,0.4284566044807434
28,2012-04-16 06:47:00,HDS is also looking outside the U.S. for potential growth with Clotamin.,0.7334306836128235,0.011066648177802563,0.25550270080566406,positive,0.7223640084266663
29,2012-04-16 06:47:00,"In early April 2012, the company signed a letter of intent with PharmaLife for the placement of Clotamin with leading pharmacies in the Russian Federation.",0.8685659170150757,0.011742917820811272,0.11969117820262909,positive,0.8568230271339417
30,2012-04-16 06:47:00,"PharmaLife, an integrated total healthcare solutions providers in Russia, is expected to secure timely product registration within the Russian Federation for Clotamin distribution and conduct local market research to support a successful product launch.",0.8948860168457031,0.011425431817770004,0.09368853271007538,positive,0.8834605813026428
31,2012-04-16 06:47:00,"If successful, HDS could see Clotamin distributed by several pharmacy and retail chains at over 400 locations in the Russian Federation.",0.5134305953979492,0.008512254804372787,0.4780571758747101,positive,0.5049183368682861
32,2012-04-16 06:47:00,"For the new Sunpeaks Ventures to execute on its business strategy and capture what we see as a significant opportunity with Clotamin, the proper management must be in place.",0.8574243187904358,0.01114225946366787,0.13143344223499298,positive,0.8462820649147034
33,2012-04-16 06:47:00,"Through HDS, Sunpeaks has established a senior management team with over a decade of experience in various positions from procurement to sales.",0.5723565816879272,0.009261456318199635,0.4183819890022278,positive,0.5630951523780823
34,2012-04-16 06:47:00,"In February 2012, Mr. Machie Barch was named the company's CEO.",0.055275868624448776,0.006830757483839989,0.9378933310508728,neutral,0.04844511300325394
35,2012-04-16 06:47:00,"Mr. Barch, the company's majority shareholder, is a co-founder of HDS.",0.02981649711728096,0.006585209164768457,0.9635983109474182,neutral,0.02323128841817379
36,2012-04-16 06:47:00,"Before launching HDS, Mr. Barch was a co-founder of Global Nutritional Research, which manufactures OTC products for specific disease states based on Rx/OTC interaction.",0.04642832279205322,0.0050753322429955006,0.9484963417053223,neutral,0.04135299101471901
37,2012-04-16 06:47:00,"Mr. Barch experience ranges form pharmaceuticals and the secondary wholesaler market, to the financial services industry.",0.021972600370645523,0.00595109211280942,0.9720762968063354,neutral,0.01602150872349739
38,2012-04-16 06:47:00,He graduated the University of Colorado-Boulder with a BA in Economics.,0.17524364590644836,0.026906920596957207,0.7978494167327881,neutral,0.148336723446846
39,2012-04-16 06:47:00,"Barch currently is an elected official in the State of Maryland, serving as a City Council Member in Kensington, MD.",0.04227748140692711,0.012464889325201511,0.9452576637268066,neutral,0.029812593013048172
40,2012-04-16 06:47:00,"Barch was the President of National Blood Clot Alliance Chapter in Washington, DC, hosting charity events to raise awareness about prevalence of Thrombophilia and clot prevention.",0.28616786003112793,0.017728399485349655,0.6961036920547485,neutral,0.26843947172164917
41,2012-04-16 06:47:00,Mr Barch also serves as the company's CFO.,0.015019957907497883,0.007884788326919079,0.9770952463150024,neutral,0.007135169580578804
42,2012-04-16 06:47:00,"Other key senior management positions are held by Matthew Swift, the company's Vice President of Sales and Justin Barch, the company's Vice President at HDS.",0.01833443157374859,0.013800418004393578,0.9678651094436646,neutral,0.004534013569355011
43,2012-04-16 06:47:00,Mr.,0.04266625642776489,0.022365570068359375,0.934968113899231,neutral,0.020300686359405518
44,2012-04-16 06:47:00,"Swift is a co-founder of HDS, and was a key participant to the overall growth of two pharmaceutical wholesalers, Global Pharmaceutical Sourcing ( GPS ) and Premium Rx National ( PRN ).",0.7287846803665161,0.010226303711533546,0.2609890401363373,positive,0.7185583710670471
45,2012-04-16 06:47:00,"At GPS, Swift was able to grow sales to over $30 million 5 years.",0.9344547986984253,0.01401867251843214,0.05152656510472298,positive,0.9204361438751221
46,2012-04-16 06:47:00,He has over 10 years of senior sales position experience he has developed an experienced and competent sales force for the company.,0.8493102788925171,0.014560002833604813,0.13612964749336243,positive,0.8347502946853638
47,2012-04-16 06:47:00,Mr.,0.04266625642776489,0.022365570068359375,0.934968113899231,neutral,0.020300686359405518
48,2012-04-16 06:47:00,"Swift is a graduate of the University of Maryland, College Park with a Bachelor of Arts, Business Administration.",0.08923753350973129,0.01633843220770359,0.8944240212440491,neutral,0.07289910316467285
49,2012-04-16 06:47:00,Mr. Justin Barch is a co-founder of HDS and CEO of GNR.,0.01992054097354412,0.0073031834326684475,0.9727762937545776,neutral,0.012617357075214386
50,2012-04-16 06:47:00,"Before founding GNR, Justin was an Investment Advisor at Morgan Stanley Smith Barney in Bethesda MD, where he built investment portfolios for high net worth families.",0.09102796763181686,0.006123994942754507,0.9028480052947998,neutral,0.08490397036075592
51,2012-04-16 06:47:00,"Prior to joining MSSB, Justin spent five years at the private investment bank Johnston, Lemon & Co. Inc in Washington, DC where he was an investment advisor.",0.05098873749375343,0.008663157001137733,0.9403481483459473,neutral,0.04232557862997055
52,2012-04-16 06:47:00,Justin is a graduate of the A.B.,0.057253170758485794,0.02498765103518963,0.9177591800689697,neutral,0.032265521585941315
53,2012-04-16 06:47:00,Freeman School of Business at Tulane University where he majored in finance and minored in accounting.,0.08387848734855652,0.03790346905589104,0.8782180547714233,neutral,0.04597501829266548
54,2012-04-16 06:47:00,"In his spare time Justin advocates for blood clot awareness, and was recently elected to the board of directors of the National Blood Clot Alliance.",0.23045344650745392,0.013516373932361603,0.7560302019119263,neutral,0.21693706512451172
55,2012-04-16 06:47:00,"Since the acquisition of HDS in February 2012, Sunpeaks has been active in securing financing to execute it's business plan with Clotamin.",0.8160138726234436,0.01014916691929102,0.17383694648742676,positive,0.805864691734314
56,2012-04-16 06:47:00,"In March 2012, the company issued a three-year 10% convertible note in with an original principal amount of $200,000 to an investor.",0.03850961849093437,0.005932654719799757,0.9555577039718628,neutral,0.03257696330547333
57,2012-04-16 06:47:00,"The note is convertible into shares of our common stock based on a conversion price that is equal to a 20% discount to the average market price over a 10 day period immediately prior to the conversion date (March 1, 2014).",0.04597501456737518,0.005608426406979561,0.9484165906906128,neutral,0.04036659002304077
58,2012-04-16 06:47:00,"In April 2012, the company entered into a Convertible Promissory Note in the principal amount up to $700,000 with an interest at the rate of 10% per annum.",0.09975937008857727,0.006864277645945549,0.8933762907981873,neutral,0.09289509057998657
59,2012-04-16 06:47:00,"The note is convertible into our common stock, at the election of the Holder, at a conversion price equal to 80% of three-day average closing bid price of the common stock prior to the conversion.",0.03793717175722122,0.005720262415707111,0.9563426375389099,neutral,0.032216910272836685
60,2012-04-16 06:47:00,"Sunpeaks has since executed a draw down on the note in the amount of $175,000.",0.037804074585437775,0.2704090476036072,0.6917868852615356,neutral,-0.23260498046875
61,2012-04-16 06:47:00,Sunpeaks Ventures has a current market capitalization of approximately $750 million.,0.04522815719246864,0.004519330803304911,0.9502525329589844,neutral,0.04070882499217987
62,2012-04-16 06:47:00,The company seeks to become a significant player in the $45 billion secondary wholesale market.,0.8432470560073853,0.010933036915957928,0.14581990242004395,positive,0.8323140144348145
63,2012-04-16 06:47:00,"With only 1% market share on its over 6,000 products, Sunpeaks can achieve annual sales of $450 million.",0.0563172921538353,0.018341485410928726,0.9253412485122681,neutral,0.03797580674290657
64,2012-04-16 06:47:00,"Even with 0.5% market share, the revenue opportunity remains meaningful at $225 million.",0.7988796830177307,0.07839677482843399,0.1227235421538353,positive,0.7204828858375549
65,2012-04-16 06:47:00,"With Clotamin, the company's unique multivitamin designed for patients on warfarin and other blood thinners, we see a peak potential opportunity of $4.7 billion.",0.7999496459960938,0.010504364967346191,0.18954598903656006,positive,0.7894452810287476
66,2012-04-16 06:47:00,"With 1% penetration, the company can achieve sales totaling $47 million with Clotamin.",0.7985848188400269,0.010666796937584877,0.1907484084367752,positive,0.7879180312156677
67,2012-04-16 06:47:00,Specialty pharmaceutical companies and wholesalers typically command a price to sales ratio of three to four times sales.,0.024370649829506874,0.007654036395251751,0.967975378036499,neutral,0.016716614365577698
68,2012-04-16 06:47:00,"With peak opportunity, we think Sunpeaks Ventures could be easily worth $1 to $1.5 billion in market value.",0.4268817901611328,0.008225097320973873,0.5648931264877319,neutral,0.41865670680999756
69,2012-04-16 06:47:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
70,2012-04-16 06:47:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
